论文部分内容阅读
目的 探讨血清肿瘤标记物联合检测在非小细胞肺癌 (NSCLC)的诊断、分型、病情估价和疗效中的作用。方法 分别采用生化比色定量法、化学发光法和ELISA法 ,序贯检测 98例不同TMN分期的NSCLC患者的血清TSGF、CEA、CYFRA2 1- 1水平。结果 各型肺癌早期TSGF水平皆升高 ,但应与急性炎症相鉴别 ;CEA、CYFRA2 1- 1水平分别在腺癌和鳞癌早期即可增高 ;3项指标皆明显增高时 ,往往提示病变广泛或已为晚期。结论 结合临床和其他辅助检查 ,血清TSGF、CEA、CYFRA2 1- 1联合检测对NSCLC的早期鉴别诊断、推测病理类型、指导治疗、监测复发、判断预后有较大意义。
Objective To investigate the role of combined detection of serum tumor markers in the diagnosis, classification, disease evaluation and efficacy of non-small cell lung cancer (NSCLC). Methods Serum TSGF, CEA and CYFRA21-1 levels in 98 NSCLC patients with different TMN stages were detected sequentially by biochemical colorimetric method, chemiluminescence method and ELISA method. Results The levels of TSGF in all types of lung cancer increased early, but should be differentiated from acute inflammation; CEA, CYFRA21-1 levels could be increased in the early stage of adenocarcinoma and squamous cell carcinoma respectively; when all three indicators were significantly increased, they often suggested extensive lesions. Or already late. Conclusion Combined with clinical and other auxiliary examinations, the combined detection of serum TSGF, CEA, and CYFRA2-1-l has great significance for early differential diagnosis of NSCLC, presumed pathological type, guiding treatment, monitoring recurrence, and judging prognosis.